Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8337824 | VIFOR PHARMA | Linear polyol stabilized polyfluoroacrylate compositions |
May, 2030
(6 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8287847 | VIFOR PHARMA | Ion binding polymers and uses thereof |
Mar, 2024
(29 days ago) | |
US8778324 | VIFOR PHARMA | Ion binding polymers and uses thereof |
Mar, 2024
(29 days ago) | |
US8889115 | VIFOR PHARMA | Ion binding polymers and uses thereof |
Mar, 2024
(29 days ago) | |
US8475780 | VIFOR PHARMA | Ion binding polymers and uses thereof |
Mar, 2024
(29 days ago) | |
US10485821 | VIFOR PHARMA | Ion binding polymers and uses thereof |
Mar, 2024
(29 days ago) | |
US7556799 | VIFOR PHARMA | Ion binding polymers and uses thereof |
Feb, 2025
(9 months from now) | |
US8216560 | VIFOR PHARMA | Ion binding polymers and uses thereof |
Mar, 2027
(2 years from now) | |
US8282913 | VIFOR PHARMA | Ion binding polymers and uses thereof |
May, 2027
(3 years from now) | |
US8147873 | VIFOR PHARMA | Methods and compositions for treatment of ion imbalances |
Jun, 2028
(4 years from now) | |
US9925212 | VIFOR PHARMA | Potassium-binding agents for treating hypertension and hyperkalemia |
Oct, 2033
(9 years from now) | |
US11123363 | VIFOR PHARMA | Potassium-binding agents for treating hypertension and hyperkalemia |
Oct, 2033
(9 years from now) | |
US9492476 | VIFOR PHARMA | Potassium-binding agents for treating hypertension and hyperkalemia |
Oct, 2033
(9 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Patient Population(NPP) | Oct 02, 2026 |
New Strength(NS) | Oct 02, 2026 |
New Chemical Entity Exclusivity(NCE) | Oct 21, 2020 |
Drugs and Companies using PATIROMER SORBITEX CALCIUM ingredient
NCE-1 date: 22 October, 2019
Market Authorisation Date: 02 October, 2023
Treatment: Treatment of hyperkalemia
Dosage: POWDER;ORAL